Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Primary Ocular Adnexal MALT Lymphoma: a Multicenter Randomized Controlled Trial

NCT06190301 is registered in ClinicalTrials.gov with Zhongshan Ophthalmic Center, Sun Yat-sen University as lead sponsor.

NCT NCT06190301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06190301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Primary Ocular Adnexal MALT Lymphoma: a Multicenter Randomized Controlled Trial
Lead sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Phase
Not applicable
Overall status
Recruiting
Start date
December 20, 2023
Completion date
December 31, 2029
Enrollment
108 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary ocular adnexal malt lymphoma